Goldman Sachs Adjusts Illumina EPS, Revenue Estimates

An analyst at the investment firm said that the expanded production of Illumina's HiSeq sequencing platform is expected to result in sequential revenue growth in the first and second quarters of 2011, but revenue growth will likely abate in the third quarter.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.